PD-1 inhibition in patient derived tissue cultures of human gastric and gastroesophageal adenocarcinoma

References

• Ho SWT, Tan P. Dissection of gastric cancer heterogeneity for precision oncology. Cancer Science. 2019;110(11):3405–11. doi:10.1111/cas.14191.
   PubMed Web of Science ®Google Scholar
• Ychou M, Boige V, Pignon J-P, Conroy T, Bouché O, Lebreton G et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2011;29:1715–1721. doi:10.1200/JCO.2010.33.0597.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2018;68:394–424. doi:10.3322/caac.21492.
   PubMed Web of Science ®Google Scholar
• Lordick F, Lorenzen S, Yamada Y, Ilson D. Optimal chemotherapy for advanced gastric cancer: is there a global consensus? Gastric Cancer: Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2014;17(2):213–225. doi:10.1002/cam4.720.
   PubMed Web of Science ®Google Scholar
• Roma-Rodrigues C, Mendes R, Baptista PV, Fernandes AR. Targeting Tumor Microenvironment for Cancer Therapy. International Journal of Molecular Sciences. 2019:20. doi:10.3390/ijms20040840.
   PubMed Web of Science ®Google Scholar
• Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science (New York, N.Y.). 2018;359(6382):1350–1355. doi:10.1126/science.aar4060.
   PubMed Web of Science ®Google Scholar
• Bang Y-J, Cho JY, Kim YH, Kim JW, Di Bartolomeo M, Ajani JA et al. Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 2017;23:5671–5678. doi:10.1158/1078-0432.CCR-17-0025.
   PubMed Web of Science ®Google Scholar
• Kang Y-K, Boku N, Satoh T, Ryu M-H, Chao Y, Kato Ket al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2017;390(10111):2461–2471. doi:10.1016/S0140-6736(17)31827-5.
   PubMed Web of Science ®Google Scholar
• Kawazoe A, Yamaguchi K, Yasui H, Negoro Y, Azuma M, Amagai Ket al. Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: cohort 1 data from the KEYNOTE-659 phase IIb study. European Journal of Cancer (Oxford, England: 1990). 2020;129:97–106. doi:10.1016/j.ejca.2020.02.002.
   PubMed Web of Science ®Google Scholar
• Boku N, Ryu M-H, Kato K, Chung HC, Minashi K, Lee KW et al. Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4). Annals of Oncology: Official Journal of the European Society for Medical Oncology. 2019;30:250–258. doi:10.1093/annonc/mdy540.
   PubMed Web of Science ®Google Scholar
• Moehler M, Shitara K, Garrido M, Salman P, Shen L, Wyrwicz L et al. LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): first results of the CheckMate 649 study. Annals of Oncology: Official Journal of the European Society for Medical Oncology. 2020;31:S1191. doi:10.1016/j.annonc.2020.08.2296.
   Web of Science ®Google Scholar
• Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. The Lancet Oncology. 2016;17:717–726. doi:10.1016/S1470-2045(16)00175-3.
   PubMed Web of Science ®Google Scholar
• Janjigian YY, Bendell J, Emiliano Calvo JW, Kim PA, Ascierto PS, Ott PA et al. CheckMate-032 Study: efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. Journal of Clinical Oncology 2018;36:28, 2836–2844. doi:10.1200/JCO.2017.76.6212
   Google Scholar
• Darvin P, Toor SM, Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Experimental & Molecular Medicine. 2018;50:1–11. doi:10.1038/s12276-018-0191-1.
   PubMed Web of Science ®Google Scholar
• Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. The Journal of Clinical Investigation. 2017;127:2930–2940. doi:10.1172/JCI91190.
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Pitt JM, Daillère R, Smyth MJ, Kroemer G. Mouse models in oncoimmunology. Nature Reviews. Cancer. 2016;16:759–773. doi:10.1038/nrc.2016.91.
   PubMed Web of Science ®Google Scholar
• Klinghammer K, Walther W, Hoffmann J. Choosing wisely – preclinical test models in the era of precision medicine. Cancer Treatment Reviews. 2017;55:36–45. doi:10.1016/j.ctrv.2017.02.009.
   PubMed Web of Science ®Google Scholar
• Arrowsmith J. Trial watch: phase II failures: 2008-2010. Nature reviews. Drug Discovery. 2011;10:328–329. doi:10.1038/nrd3439.
   Google Scholar
• Arrowsmith J, Miller P. Trial watch: phase II and phase III attrition rates 2011-2012. Nature reviews. Drug Discovery. 2013;12:569. doi:10.1038/nrd4090.
   Google Scholar
• Prill S, Rebstock J, Tennemann A, Körfer J, Sönnichsen R, Thieme R et al. Tumor-associated macrophages and individual chemo-susceptibility are influenced by iron chelation in human slice cultures of gastric cancer. Oncotarget. 2019;10(46):4731–4742. doi:10.18632/oncotarget.27089.
   PubMedGoogle Scholar
• Lim CY, Chang JH, Lee WS, Lee KM, Yoon YC, Kim J Park IY. Organotypic slice cultures of pancreatic ductal adenocarcinoma preserve the tumor microenvironment and provide a platform for drug response. Pancreatology: Official Journal of the International Association of Pancreatology (IAP) … [Et Al.]. 2018;18:913–927. doi:10.1016/j.pan.2018.09.009.
   PubMed Web of Science ®Google Scholar
• Sivakumar R, Chan M, Shin JS, Nishida-Aoki N, Kenerson HL, Elemento O et al. Organotypic tumor slice cultures provide a versatile platform for immuno-oncology and drug discovery. Oncoimmunology. 2019;8(12):e1670019. doi:10.1080/2162402X.2019.1670019.
   PubMed Web of Science ®Google Scholar
• Jiang X, Seo YD, Chang JH, Coveler A, Nigjeh EN, Pan S et al. Long-lived pancreatic ductal adenocarcinoma slice cultures enable precise study of the immune microenvironment. Oncoimmunology. 2017;6(e1333210). doi:10.1080/2162402X.2017.1333210
   Google Scholar
• Temann A, Golovina T, Neuhaus V, Thompson C, Chichester JA, Braun A, Yusibov V. Evaluation of inflammatory and immune responses in long-term cultured human precision-cut lung slices. Human Vaccines & Immunotherapeutics. 2017;13:351–358. doi:10.1080/21645515.2017.1264794.
   PubMed Web of Science ®Google Scholar
• Gerlach MM, Merz F, Wichmann G, Kubick C, Wittekind C, Lordick F, Bechmann I. Slice cultures from head and neck squamous cell carcinoma: a novel test system for drug susceptibility and mechanisms of resistance. British Journal of Cancer. 2014;110(2):479–488. doi:10.1038/bjc.2013.700.
   PubMed Web of Science ®Google Scholar
• Koerfer J, Kallendrusch S, Merz F, Wittekind C, Kubick C, Kassahun WT et al. Organotypic slice cultures of human gastric and esophagogastric junction cancer. Cancer Medicine. 2016;5:1444–1453. doi:10.1002/cam4.720.
   PubMed Web of Science ®Google Scholar
• Merz F, Gaunitz F, Dehghani F, Renner C, Meixensberger J, Gutenberg Aet al. Organotypic slice cultures of human glioblastoma reveal different susceptibilities to treatments. Neuro Oncol. 2013;15(6):670–681. doi:10.1093/neuonc/not003.
   PubMed Web of Science ®Google Scholar
• Sönnichsen R, Hennig L, Blaschke V, Winter K, Körfer J, Hähnel S et al. Individual Susceptibility Analysis Using Patient-derived Slice Cultures of Colorectal Carcinoma. Clinical Colorectal Cancer . 2018;17(2):e189–e199. doi:10.1016/j.clcc.2017.11.002.
   PubMed Web of Science ®Google Scholar
• Karekla E, Liao W-J, Sharp B, Pugh J, Reid H, Quesne JL et al. Ex Vivo Explant Cultures of Non–Small Cell Lung Carcinoma Enable Evaluation of Primary Tumor Responses to Anticancer Therapy. Cancer Research. 2017;77(8):2029–2039. doi:10.1158/0008-5472.CAN-16-1121.
   PubMed Web of Science ®Google Scholar
• Roelants C, Pillet C, Franquet Q, Sarrazin C, Peilleron N, Giacosa, S et al. Ex-Vivo Treatment of Tumor Tissue Slices as a Predictive Preclinical Method to Evaluate Targeted Therapies for Patients with Renal Carcinoma. Cancers. 2020;12. doi:10.3390/cancers12010232.
   PubMed Web of Science ®Google Scholar
• Cui C, Xu C, Yang W, Chi Z, Sheng X, Si L et al. Ratio of the interferon- γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma. npj Genom. Med.2021;6 (1):S.7. doi:10.1038/s41525-021-00169-w.
   Google Scholar
• Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nature Reviews. Drug Discovery. 2019;18:197–218. doi:10.1038/s41573-018-0007-y.
   PubMed Web of Science ®Google Scholar
• Martínez-Lostao L, Anel A, How PJ. Do Cytotoxic Lymphocytes Kill Cancer Cells? Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 2015;21:5047–5056. doi:10.1158/1078-0432.CCR-15-0685.
   PubMed Web of Science ®Google Scholar
• Farhood B, Najafi M, Mortezaee K. CD8+ cytotoxic T lymphocytes in cancer immunotherapy: a review. Journal of Cellular Physiology. 2019;234:8509–8521. doi:10.1002/jcp.27782.
   PubMed Web of Science ®Google Scholar
• Mittrücker H-W, Visekruna A, Huber M. Heterogeneity in the differentiation and function of CD8⁺ T cells. Archivum Immunologiae Et Therapiae Experimentalis. 2014;62:449–458. doi:10.1007/s00005-014-0293-y.
   PubMed Web of Science ®Google Scholar
• Golstein P, Griffiths GM. An early history of T cell-mediated cytotoxicity. Nature Reviews Immunology. 2018;18(8):527–535. doi:10.1038/s41577-018-0009-3.
   PubMed Web of Science ®Google Scholar
• Hickman JA, Graeser R, de Hoogt R, Vidic S, Brito C, Gutekunst M, van der Kuip H. Three-dimensional models of cancer for pharmacology and cancer cell biology: capturing tumor complexity in vitro/ex vivo. Biotechnology Journal. 2014;9:1115–1128. doi:10.1002/biot.201300492.
   PubMed Web of Science ®Google Scholar
• Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell 168, 707–723. 2017. doi:10.1016/j.cell.2017.01.017.
   Google Scholar
• McMillin DW, Negri JM, Mitsiades CS. The role of tumour–stromal interactions in modifying drug response: challenges and opportunities. Nature Reviews Drug Discovery. 2013;12(3):217–228. doi:10.1038/nrd3870.
   PubMed Web of Science ®Google Scholar
• Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008;27(45):5904–5912. doi:10.1038/onc.2008.271.
   PubMed Web of Science ®Google Scholar
• Whiteside TL, Demaria S, Rodriguez-Ruiz ME, Zarour HM, Melero I. Emerging Opportunities and Challenges in Cancer Immunotherapy. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2016;22:1845–1855. doi:10.1158/1078-0432.CCR-16-0049.
   PubMed Web of Science ®Google Scholar
• Kelderman S, Schumacher TNM, Haanen JBAG. Acquired and intrinsic resistance in cancer immunotherapy. Molecular Oncology. 2014;8:1132–1139. doi:10.1016/j.molonc.2014.07.011.
   PubMed Web of Science ®Google Scholar
• Chaudhary B, Elkord E. Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: role and Therapeutic Targeting. Vaccines. 2016:4. doi:10.3390/vaccines4030028.
   Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. The New England Journal of Medicine. 2015;373:23–34. doi:10.1056/NEJMoa1504030.
   PubMed Web of Science ®Google Scholar
• Larkin J, Lao CD, Urba WJ, McDermott DF, Horak C, Jiang J, Wolchok JD et al. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: a Pooled Analysis of 4 Clinical Trials. JAMA Oncology. 2015;1:433–440. doi:10.1001/jamaoncol.2015.1184.
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Mathew D, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim S-W, Carcereny Costa E et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. The New England Journal of Medicine. 2019;381:2020–2031. doi:10.1056/NEJMoa1910231.
   PubMed Web of Science ®Google Scholar
• D’Errico G, Machado HL, Sainz B. A current perspective on cancer immune therapy: step-by-step approach to constructing the magic bullet. Clinical and Translational Medicine. 2017;6(3). doi:10.1186/s40169-016-0130-5.
   PubMedGoogle Scholar
• Hartley GP, Chow L, Ammons DT, Wheat WH, Dow SW. Programmed Cell Death Ligand 1 (PD-L1) Signaling Regulates Macrophage Proliferation and Activation. Cancer Immunology Research. 2018;(6)1260–1273. doi:10.1158/2326-6066.CIR-17-0537.
   PubMedGoogle Scholar
• Davis Z, Felices M, Lenvik T, Badal S, Walker JT, Hinderlie P et al. Low-density PD-1 expression on resting human natural killer cells is functional and upregulated after transplantation. Blood Advances. 2021;(5):1069–1080. doi:10.1182/bloodadvances.2019001110.
   PubMedGoogle Scholar
• Shen H, Yang E S-H, Conry M, Fiveash J, Contreras C, Bonner JA, Shi LZ. Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies. Genes & Diseases. 2019;6:232–246. doi:10.1016/j.gendis.2019.06.006.
   PubMed Web of Science ®Google Scholar
• Murciano-Goroff YR, Warner AB, Wolchok JD. The future of cancer immunotherapy: microenvironment-targeting combinations. Cell Research. 2020;30(6):507–519. doi:10.1038/s41422-020-0337-2.
   PubMed Web of Science ®Google Scholar
• Schirrmacher V. From chemotherapy to biological therapy: a review of novel concepts to reduce the side effects of systemic cancer treatment (Review). International Journal of Oncology. 2019;54:407–419. doi:10.3892/ijo.2018.4661.
   PubMed Web of Science ®Google Scholar
• Dosset M, Vargas TR, Lagrange A, Boidot R, Végran F, Roussey A et al. PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer. Oncoimmunology. 2018;7(e1433981). doi:10.1080/2162402X.2018.1433981
   PubMedGoogle Scholar
• Limagne E, Thibaudin M, Nuttin L, Spill A, Derangêre V, Furnet J-D et al. Trifluridine/Tipiracil plus Oxaliplatin Improves PD-1 Blockade in Colorectal Cancer by Inducing Immunogenic Cell Death and Depleting Macrophages. Cancer Immunology Research. 2019;7:1958–1969. doi:10.1158/2326-6066.CIR-19-0228.
   PubMed Web of Science ®Google Scholar
• Swart M, Verbrugge I, Beltman JB. Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy. Frontiers in Oncology. 2016;6:233. doi:10.3389/fonc.2016.00233.
   PubMed Web of Science ®Google Scholar
• Majumder B, Baraneedharan U, Thiyagarajan S, Radhakrishnan P, Narasimhan H, Dhandapani M et al. Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity. Nature Communications. 2015;6:6169. doi:10.1038/ncomms7169.
   PubMed Web of Science ®Google Scholar